OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SLGL
Sol-Gel Technologies Ltd.
There isn't enough reported data to score SLGL yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SLGL Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
SLGL's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SLGL PE Valuation
SLGL has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SLGL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect SLGL's losses to grow, with revenue declining.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SLGL on earnings quality, reporting a profit while its opponent remains loss making.
SLGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.64 | -$4.38 |
| Q4 2023 | -$10.10 | -$3.64 |
| Q3 2023 | -$10.90 | -765% |
| Q2 2023 | -$10.30 | -379% |
| Q1 2023 | -$8.16 | -3500% |
| Q4 2022 | -$6.46 | -869% |
| Q3 2022 | $1.64 | +$9.20 |
| Q2 2022 | $3.69 | +$15.49 |
SLGL is still losing money, but far less than before: $5.64 per share over the past year, against $15.60 at its worst in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SLGL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SLGL on profitability, with a higher operating margin.
SLGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $591K | -97% |
| Q1 2026 | $108K | -90% |
| Q4 2025 | $696K | +150% |
| Q3 2025 | $400K | -93% |
| Q2 2025 | $17.3M | +218% |
| Q1 2025 | $1M | +121% |
| Q4 2024 | $278K | -38% |
| Q3 2024 | $5.4M | +2417% |
SLGL's revenue has slid since its 2021 peak: $591,000 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -704% | -769 points |
| Q1 2026 | -3569% | -2690 points |
| Q4 2025 | -490% | +1704 points |
| Q3 2025 | -1572% | -1557 points |
| Q2 2025 | 65% | +35 points |
| Q1 2025 | -880% | -2320 points |
| Q4 2024 | -2194% | -984 points |
| Q3 2024 | -15% | +2946 points |
SLGL's operating margin was −704% last quarter, down 769 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with SLGL at up 100%.
SLGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2024 | $0 | $0 |
| Q1 2024 | $0 | $0 |
| Q4 2023 | $0 | $0 |
| Q3 2023 | $0 | $0 |
| Q2 2023 | $0 | $0 |
| Q1 2023 | $0 | $0 |
| Q4 2022 | $0 | +$15.8M |
| Q3 2022 | $0 | $0 |
SLGL's free cash flow was $0 over the past year, against $0 the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SLGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +434K shares |
| 1 year | +17% | +485K shares |
| 3 years | +41% | +958K shares |
| 5 years | +42% | +970K shares |
| Available history | +65% | +1.3M shares |
SLGL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SLGL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -10.4x | Net Cash |
| Q3 2024 | -4.8x | Net Cash |
| Q3 2022 | -1.6x | Net Cash |
| Q2 2022 | -0.5x | Net Cash |
| Q1 2022 | -9.2x | Net Cash |
| Q4 2021 | -4.8x | Net Cash |
SLGL has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SLGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 15.5 | Oversold |
SLGL's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SLGL PE vs Healthcare Sector
| Metric | SLGL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SLGL has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SLGL on trend strength, trading above more of its moving averages.
SLGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.2 | 15% below |
| 20 week MA | $72.0 | 22% below |
| 50 week MA | $69.9 | 20% below |
| 100 week MA | $42.6 | 32% above |
| 200 week MA | $30.7 | 83% above |
SLGL has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 83% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SLGL on returns for 2026, with the stronger performance.
SLGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.3 | $95.0 | +2.9% |
| 2021 | $95.0 | $67.4 | -29% |
| 2022 | $67.4 | $45.0 | -33% |
| 2023 | $45.0 | $11.1 | -75% |
| 2024 | $11.1 | $11.2 | +0.9% |
| 2025 | $11.2 | $41.9 | +274% |
| 2026 YTD | $41.9 | $56.3 | +34% |
SLGL's yearly returns have swung widely, from +274% in 2025 to −75% in 2023. It's up 34% so far in 2026.